2014
Patterns of Care Quality and Prognosis Among Hospitalized Ischemic Stroke Patients With Chronic Kidney Disease
Ovbiagele B, Schwamm L, Smith E, Grau‐Sepulveda M, Saver J, Bhatt D, Hernandez A, Peterson E, Fonarow G. Patterns of Care Quality and Prognosis Among Hospitalized Ischemic Stroke Patients With Chronic Kidney Disease. Journal Of The American Heart Association 2014, 3: e000905. PMID: 24904017, PMCID: PMC4309090, DOI: 10.1161/jaha.114.000905.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseIschemic stroke patientsSevere renal dysfunctionGlomerular filtration rateStroke patientsRenal dysfunctionQuality of careKidney diseaseHospitalized ischemic stroke patientsGuideline-based therapyGuideline-recommended therapiesGuidelines-Stroke programGWTG-Stroke programStroke performance measuresHospital mortality rateNormal kidney functionHospital mortalityHospital prognosisInpatient mortalityIschemic strokeCare complianceKidney functionModerate dysfunctionKidney failureFiltration rate
2011
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
Leal T, Remick S, Takimoto C, Ramanathan R, Davies A, Egorin M, Hamilton A, LoRusso P, Shibata S, Lenz H, Mier J, Sarantopoulos J, Mani S, Wright J, Ivy S, Neuwirth R, von Moltke L, Venkatakrishnan K, Mulkerin D. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemotherapy And Pharmacology 2011, 68: 1439-1447. PMID: 21479634, PMCID: PMC3481841, DOI: 10.1007/s00280-011-1637-5.Peer-Reviewed Original ResearchConceptsSevere renal dysfunctionNormal renal functionRenal dysfunctionAdult cancer patientsRenal functionDialysis patientsDose escalationCancer patientsPatient populationNational Cancer Institute Organ Dysfunction Working Group StudyDose of bortezomibImpaired renal functionGeneral patient populationIntravenous bortezomibRenal impairmentCreatinine clearanceModerate dysfunctionMild dysfunctionSevere dysfunctionDose reductionPharmacologic dataPatientsDay 1DysfunctionBortezomib
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply